drugset
drugset / Trial / NCT00143390

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

NCT00143390 ↗

Phase 3 Completed 298 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To verify the non-inferiority of exemestane compared to anastrozole in time to tumor progression (TTP), the primary efficacy endpoint, in postmenopausal women with advanced/recurrent breast cancer.

Timeline

Start
2005-04
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Exemestane Small molecule 25 mg Oral

Indications

breast neoplasm